Number of the records: 1
cetuximab
SYS d000068818 LBL 00000nz--a2200181n--4500 005 20250606221739.5 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.750 065 $a D12.776.124.790.651.114.224.060.750 065 $a D12.776.377.715.548.114.224.200.750 066 $a 01 $c 03 150 $a cetuximab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a C225 $2 slo 550 $7 sllk_us_auth*d000074322 $Y Antineoplastic Agents, Immunological $w P $a antineoplastiká imunologické 550 $7 sllk_us_auth*d066246 $Y ErbB Receptors $w p $a receptory erbB 665 $a 2016 (2000) $2 eng 680 9-
$i A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. $2 eng 750 -2
$a Cetuximab $2 eng 980 $x M
Number of the records: 1